Literature DB >> 7697234

Early pulmonary inflammation in infants with cystic fibrosis.

T Z Khan1, J S Wagener, T Bost, J Martinez, F J Accurso, D W Riches.   

Abstract

The mechanisms underlying the initiation of lung disease and early respiratory morbidity in cystic fibrosis (CF) are poorly understood. By identifying infants with CF through a statewide neonatal screening program, we investigated whether airway inflammation was present in these infants, with the goal of furthering our understanding of the early events in this lung disease. Bronchoalveolar lavage fluid (BALF) from 16 infants with CF (mean age, 6 mo) and 11 disease control infants (mean age, 12 mo) was examined for the following inflammatory parameters: (1) neutrophil count; (2) activity of free neutrophil elastase; (3) elastase/alpha 1-antiprotease inhibitor complexes; and (4) the level of interleukin-8 (IL-8). We also quantified the spontaneous level of expression of IL-8 mRNA transcripts by airway macrophages. Each index of airway inflammation was increased in the BALF of infants with CF as compared with control infants. In addition, both the number of neutrophils and IL-8 levels were increased in infants with CF who had negative cultures (n = 7) for common bacterial CF-related pathogens, as well as for common respiratory viruses and fungi at the time of bronchoalveolar lavage (BAL). These findings suggest that airway inflammation is already present in infants with CF who are as young as 4 wks. Furthermore, although many different cell types (e.g., epithelial cells) may express IL-8, airway macrophages appear to be a source of this chemokine, and may thus play a prominent role in early neutrophil influx into the lung.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697234     DOI: 10.1164/ajrccm/151.4.1075

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  313 in total

Review 1.  Physiotherapy in cystic fibrosis.

Authors:  S A Prasad; E L Tannenbaum; C Mikelsons
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.

Authors:  Torsten H Schroeder; Martin M Lee; Patrick W Yacono; Carolyn L Cannon; A Alev Gerçeker; David E Golan; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

3.  Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa.

Authors:  C Hubeau; M Lorenzato; J P Couetil; D Hubert; D Dusser; E Puchelle; D Gaillard
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  Regional differences in the evolution of lung disease in children with cystic fibrosis.

Authors:  Zhanhai Li; Don B Sanders; Michael J Rock; Michael R Kosorok; Jannette Collins; Christopher G Green; Alan S Brody; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-12-07

Review 5.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

Review 6.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 7.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 8.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Control the platelets, control the disease: A novel cystic fibrosis hypothesis.

Authors:  Siobhan Branfield; A Valance Washington
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

10.  Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa.

Authors:  S Jain-Vora; A M LeVine; Z Chroneos; G F Ross; W M Hull; J A Whitsett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.